DR. REDDYS LAB Surges by 5%; BSE HEALTHCARE Index Up 1.5%

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  •
  • MyStocks
MEMBER'S LOGIN

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

DR. REDDYS LAB Surges by 5%; BSE HEALTHCARE Index Up 1.5%
Tue, 24 Mar 09:40 AM

DR. REDDYS LAB share price has zoomed 5% and is presently trading at Rs 2,958.

Meanwhile, the BSE HEALTHCARE Index is at 11,583 (up 1.5%).

Among the top Gainers in the BSE HEALTHCARE Index today are DR. REDDYS LAB (up 4.9%) and PROCTER & GAMBLE HEALTH (up 5.4%).

LAURUS LABS LTD (down 0.2%) and NATCO PHARMA (down 0.4%) are among the top losers today.

Over the last one year, DR. REDDYS LAB has moved up from Rs 2,779 to Rs 2,958, registering a gain of Rs 179 (up 4.4%).

On the other hand, the BSE HEALTHCARE has moved down from 14,114 to 11,583, loss of 2,531 points (down 20.8%) during the last 12 months.

The top gainers among the BSE HEALTHCARE Index stocks during this same period were ABBOTT INDIA (up 85.0%), IPCA LABS (up 40.5%) and J.B.CHEMICALS (up 38.3%).

Going Live Today: India's #1 trader reveals how to profit during the Corona Crisis. Click here to register for free.

What About the Benchmark Indices?

The BSE Sensex is at 27,463 (up 0.9%).

The top gainers among the BSE Sensex stocks today are HUL (up 6.0%), HCL TECHNOLOGIES (up 5.6%) and INFOSYS (up 5.6%). Other gainers include TECH MAHINDRA (up 4.7%) and MARUTI SUZUKI (up 3.3%). The most traded stocks in the BSE Sensex are SBI and ONGC.

In the meantime, NSE Nifty is at 8,037 (up 1.1%). The top gainers in the NSE Nifty include HUL (up 6.2%), HCL TECHNOLOGIES (up 5.8%) and INFOSYS (up 5.6%). Other gainers include TECH MAHINDRA (up 5.3%) and DR. REDDYS LAB (up 4.8%) are among the top gainers in NSE Nifty.

Over the last 12 months, the BSE Sensex has moved down from 37,809 to 27,463, registering a loss of 10,346 points (down 30.68%).

DR. REDDYS LAB Financial Update...

DR. REDDYS LAB net profit down at Rs 6 billion for the quarter ended December 2019, compared to a loss of Rs 5 billion a year ago. Net Sales rose 13.8% to Rs 44.0 billion during the period as against Rs 38.6 billion in October-December 2018.

For the year ended March 2019, DR. REDDYS LAB reported 108.9% increase in net profit to Rs 19.1 billion compared to net profit of Rs 9.1 billion during FY18.

Revenue of the company grew 8.2% to Rs 154 billion during FY19.

The current Price to earnings ratio of DR. REDDYS LAB, based on rolling 12 month earnings, stands at 29.4x.

Archives

RSS RSS



What else is happening in the markets today? Dig in...

Advertisement
Today is the Big Day...
Today at 5 PM, India's #1 trader will reveal his Personal Trading Blueprint... he's been using it for the last 30 years to identify trades with that have made gains like: Rs 63,400 in 1 day... Rs 51,450 in less than 12 hours... Rs 44,650 in less than 12 hours and more. If you'd like to see exactly how he does it – Click here to register for the Weekly Cash Summit

*past performance does not guarantee future results.

Equitymaster requests your view! Post a comment on "DR. REDDYS LAB Surges by 5%; BSE HEALTHCARE Index Up 1.5%". Click here!

  

Stock Market Updates

Volatile Day for Indian Indices: Sensex Ends 131 Points Lower Post Rebound; Telecom and Auto Stocks Bleed (Today's Market)

Mar 27, 2020 Closing

It was a volatile day for India share markets today. The benchmark indices opened higher but turned volatile.

DR. LAL PATHLABS LTD Surges by 5%; BSE HEALTHCARE Index Up 0.5% (Today's Market)

Mar 27, 2020 03:34 PM

DR. LAL PATHLABS LTD share price has surged by 5% and its current market price is Rs 1,571. The BSE HEALTHCARE is up by 0.5%. The top gainers in the BSE HEALTHCARE Index are DR. LAL PATHLABS LTD (up 5.2%) and AJANTA PHARMA (up 6.2%). The top losers are ALEMBIC PHARMA (down 0.1%) and DR. REDDYS LAB (down 0.2%).

TEAMLEASE SERVICES Plunges by 10%; BSE 500 Index Down 0.2% (Today's Market)

Mar 27, 2020 03:34 PM

TEAMLEASE SERVICES share price has plunged by 10% and its current market price is Rs 1,777. The BSE 500 is down by 0.2%. The top gainers in the BSE 500 Index are SHRIRAM TRANSPORT (up 12.6%) and MMTC LTD (up 12.2%). The top losers are TEAMLEASE SERVICES (down 10.2%) and MAHARASHTRA SEAMLESS (down 14.4%).

NESCO Plunges by 6%; BSE CAPITAL GOODS Index Down 0.3% (Today's Market)

Mar 27, 2020 03:30 PM

NESCO share price has plunged by 6% and its current market price is Rs 520. The BSE CAPITAL GOODS is down by 0.3%. The top gainers in the BSE CAPITAL GOODS Index are BHARAT ELECTRONICS (up 9.0%) and FINOLEX CABLES (up 6.6%). The top losers are NESCO (down 5.9%) and AIA ENGINEERING (down 5.3%).

SIEMENS Plunges by 5%; BSE CAPITAL GOODS Index Down 0.3% (Today's Market)

Mar 27, 2020 03:18 PM

SIEMENS share price has plunged by 5% and its current market price is Rs 1,165. The BSE CAPITAL GOODS is down by 0.3%. The top gainers in the BSE CAPITAL GOODS Index are BHARAT ELECTRONICS (up 8.7%) and FINOLEX CABLES (up 6.7%). The top losers is SIEMENS (down 5.1%).

PFIZER Plunges by 5%; BSE HEALTHCARE Index Down 0.4% (Today's Market)

Mar 27, 2020 03:12 PM

PFIZER share price has plunged by 5% and its current market price is Rs 4,000. The BSE HEALTHCARE is down by 0.4%. The top gainers in the BSE HEALTHCARE Index are GRANULES INDIA (up 10.6%) and CAPLIN POINT (up 7.4%). The top losers are PFIZER (down 5.2%) and APOLLO HOSPITALS (down 6.0%).

View More Indian Share Market News

Most Popular

This Crorepati Stock Could Be the Best Vaccine for Your Portfolio Against Coronavirus(Profit Hunter)

Mar 17, 2020

If there is one stock I had to recommend you amid Coronavirus outbreak, this would be it.

If I Were to Recommend One Stock Amid Coronavirus Outbreak, This Would be It.(Profit Hunter)

Mar 19, 2020

Coronavirus outbreak has made no impact on the long term prospects of my favourite smallcap. What it has indeed done is brought the company below my buy price, making it even more attractive investment at current price.

Why India Will Be the Biggest Winner in a Post-Coronavirus World(The 5 Minute Wrapup)

Mar 19, 2020

The way businesses operate will change in a major way post the coronavirus impact. Here's why India stands to benefit from this change...

A Big Trading Opportunity is Coming Your Way Soon(Fast Profits Daily)

Mar 25, 2020

I see a big opportunity to make fast profits on the horizon.

The Biggest Trading Opportunity of 2020 is Here...

Mar 26, 2020

India's #1 trader, Vijay Bhambwani, talks about a hugely profitable trading opportunity which you must know about today!

More

How to Trade the
Coronavirus Crash

Coronavirus Crash
Get this special report, authored by Equitymaster's top analysts, now.
We will never sell or rent your email id.
Please read our Terms

OUR TOP 5 IDEAS

How to Trade the Coronavirus Crash - Download this FREE Report Now
How to Profit Even During These Times of Crisis: Vijay Bhambwani Reveals his Strategy...
The Best Stocks For 2020 - How to Spot Multibagger Ideas. FREE Sign up!
Free Report: The Secret to Increasing Your Trading Profits Daily!
Find Out Our Top 7 Bluechips for 2020 Virtually FREE. Click Here Now!

S&P BSE SENSEX


Mar 27, 2020 (Close)

OTHER USEFUL LINKS

MARKET STATS


ABOUT EQUITYMASTER

Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.

FREE NEWSLETTERS
PREMIUM PRODUCTS
QUICK LINKS
APPS
  • Get Equitymaster Android App on Google Play
  • Get Equitymaster iOS App on App Store
FOLLOW

Copyright © Equitymaster Agora Research Private Limited.

Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap

Equitymaster Agora Research Private Limited (Research Analyst) 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407

All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.

SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.